# Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination

> **NCT06167915** · PHASE1 · UNKNOWN · sponsor: **Guangzhou Patronus Biotech Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- SARS-CoV-2
- COVID-19 Vaccine

## Interventions

- **BIOLOGICAL:** 30μg dose of LYB002V14
- **BIOLOGICAL:** 60μg dose of LYB002V14
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT06167915
- **Lead sponsor:** Guangzhou Patronus Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-26
- **Primary completion:** 2024-12-26
- **Final completion:** 2024-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06167915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06167915, "Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06167915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*